Compare USNA & OCGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | USNA | OCGN |
|---|---|---|
| Founded | 1992 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 371.5M | 387.3M |
| IPO Year | 1996 | N/A |
| Metric | USNA | OCGN |
|---|---|---|
| Price | $22.13 | $1.71 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $36.00 | $7.00 |
| AVG Volume (30 Days) | 134.8K | ★ 5.7M |
| Earning Date | 02-17-2026 | 03-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.90 | N/A |
| Revenue | ★ $912,670,000.00 | $5,370,000.00 |
| Revenue This Year | $9.80 | $35.88 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $24.40 | ★ N/A |
| Revenue Growth | 5.88 | ★ 14.26 |
| 52 Week Low | $18.48 | $0.52 |
| 52 Week High | $38.32 | $1.96 |
| Indicator | USNA | OCGN |
|---|---|---|
| Relative Strength Index (RSI) | 68.10 | 58.56 |
| Support Level | $20.19 | $1.58 |
| Resistance Level | $21.35 | $1.96 |
| Average True Range (ATR) | 0.70 | 0.15 |
| MACD | 0.25 | 0.02 |
| Stochastic Oscillator | 92.57 | 60.16 |
Usana Health Sciences Inc is a direct selling and direct-to-consumer nutrition, personal health and wellness company. It developed and manufactured science-based nutritional, personal care and skincare products with a focus on promoting long-term health and wellness. The company has two reportable segments: direct selling and Hiya direct-to-consumer. The direct selling segment develops and manufactures high quality, science-based nutritional, personal care and skincare products with a focus on promoting long-term health and wellness in various geographic markets that are distributed through the direct selling channel. The Hiya direct-to-consumer segment is a provider of children's health and wellness products in the U.S. Key revenue is generated from Direct selling segment.
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").